A group of cardiologists, neuropsychologists, psychiatrists, and patient partners just published a consensus statement in the Journal of the American Heart Association that says, in so many words, what most of us have been saying for years: adults with congenital heart disease are not getting the mental health and cognitive support they need, and nobody really knows what interventions actually work for us.
That's not a criticism. It's a starting point. And the paper lays out a surprisingly honest roadmap for what needs to happen next.
What This Paper Actually Is
In April 2024, a working group of clinicians and CHD patients met in Atlanta for a two-day conference focused specifically on neurocognitive and psychological interventions for adults with CHD. The group included neuropsychologists from Emory, Mayo Clinic, and Cincinnati Children's, cardiologists from Mount Sinai and Boston Children's/Brigham and Women's, a psychiatrist from the University of Rochester, and three adults living with CHD through the Adult Congenital Heart Association. I was one of those patient partners, though the heavy lifting here was done by the clinicians and researchers who spent months synthesizing the literature and identifying where the gaps are.
The result is a consensus statement organized around five critical questions, each with a summary of what we know, what we don't, and what needs to happen. You can (and should) read the full paper here.
The Five Questions That Matter
The paper tackles these head-on: (i) what interventions improve neurocognitive functioning; (ii) what interventions improve psychological well-being; (iii) what do we know about whether psych meds are safe and effective for us; (iv) what can improve health literacy; and (v) what are the barriers keeping people from accessing care that does exist.
The honest answer to most of these, right now, is "we don't have enough data." Physical exercise and cognitive rehabilitation show promise in the general population, but almost none of that research has been done specifically with CHD adults. There's been exactly one study looking at antidepressant effectiveness in ACHD patients. One. No published clinical trials or large prospective studies have examined the safety and efficacy of psychotropic medications in adults with CHD. Providers are borrowing guidelines from other populations and doing their best.
That's not a comfortable thing to read if you're currently on an SSRI or a stimulant for ADHD and you have a complex heart history. But it's better to know the landscape than to assume someone has studied it when they haven't.
Why This Hits Different for CHD Adults
Here's what makes this population unique, and what the paper captures well. Many of us grew up with neurodevelopmental delays that never fully resolved. The cognitive challenges we had as kids didn't just disappear because we turned 18. They followed us into adulthood, affecting education, employment, and quality of life. And they interact with psychological symptoms in ways that compound each other (executive dysfunction plus anxiety is a brutal combination, and anyone living it already knows that).
On top of that, there's the exercise fear problem. The general population benefits from physical activity for cognitive and mental health. But CHD patients often grew up being told to be careful, to sit out, to not push it. That fear doesn't go away easily, and it creates a real barrier to interventions that might otherwise help.
Then there's the transition gap. An estimated 39% of young adults with CHD get lost in the handoff between pediatric and adult care. The pediatric side has built robust support systems over the last two decades (neurodevelopmental evaluations, school liaisons, family programs, summer camps). The adult side has almost none of that infrastructure. The paper includes a figure showing the contrast, and it's stark.
What You Should Know
- Cognitive behavioral therapy, acceptance and commitment therapy, EMDR, and mindfulness-based interventions all have evidence in other cardiac populations, but haven't been rigorously tested in CHD adults specifically.
- Selected SSRIs (escitalopram and sertraline) have been found effective for depression in adults with acquired heart disease without significant cardiovascular side effects, but long-term data for CHD patients is missing.
- Stimulant medications for ADHD appear safe short-term in the CHD population, but long-term cardiovascular safety hasn't been studied, especially for those prescribed since childhood.
- Health literacy is a major issue: between 36% and 88% of U.S. adults have insufficient health literacy to navigate the healthcare system, and CHD patients face additional complexity from neurodevelopmental factors and decades of medical management.
- The paper explicitly calls for community-based participatory research, meaning patients and families should be part of designing the interventions, not just receiving them.
Where This Goes From Here
The paper's "next steps" read like a research agenda for the next decade. Multicenter randomized controlled trials. Prescribing guidelines for psychiatric medications in ACHD. Validated health literacy measures. Surveys of what ACHD centers are actually providing (and what they're not). Alternative delivery methods like telehealth. Partnerships with patient organizations.
It's a lot. And it's honest about the fact that these interventions are expensive and resource-intensive, and that provider shortages are real. But the paper makes a point worth repeating: the cost of neglecting these needs is higher. Poor psychological health, cognitive impairments, and low health literacy lead to worse outcomes and higher healthcare costs downstream.
If you're an adult with CHD, or you love someone who is, this paper is worth your time. It's dense, it's academic, and it's not a light read. But it represents a group of people who are trying to build the evidence base that our community needs. That matters.
